Strain Background: C57BL/6N
The double-humanized PD-1 and CTLA-4 mouse model (hPD-1/hCTLA-4) was generated by intercrossing hPD-1 and hCTLA-4 mice.
Research and Application:
The hPD-1/hCTLA-4 mouse enables the in vivo efficacy and safety assessment of compounds targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.
Use our hPD-1/hCTLA-4 mouse model together with cell line MC38-hPD-L1 as a syngeneic tumor model for testing the efficacy of combination therapies targeting human PD-1 and human PD-L1.
Figure 1. hPD-1 and hCTLA-4 expression patterns in hPD-1/hCTLA-4 mice recapitulate mPD-1 and mCTLA-4 in wild-type mice. Splenocytes from wildtype and hPD-1/hCTLA-4 double homozygous mice were activated with αCD3/αCD29. Expression of both hPD-1 and hCTLA-4 in CD4conv T cells of hPD-1/hCTLA-4 mice, and mPD-1 and mCTLA-4 expression in CD4conv T cells of wildtype mice are shown.
Figure 2. hPD-1 and hCTLA-4 are expressed on TILs (tumor-infiltrating lymphocytes). PD-1 and CTLA-4 expression on TILs from mice bearing MCA205 tumors. Mouse and human PD-1 and CTLA-4 expression were analyzed on wild-type and hPD-1/hCTLA-4 mice.
Figure 3. Intracranial transplantation of GL261 murine glioma cells into wild-type and hPD-1/hCTLA-4 homozygous mice. After transplantation, wild-type mice are treated with mouse PD-1 monoclonal antibody and injection of αhPD-1 (pembrolizumab) in hPD-1/hCTLA-4 homozygous mice to inhibit tumor growth and extend the lifespan of the mice.
Figure 4. Subcutaneous transplantation of MC38 murine colorectal cancer cells into wild-type and hCTLA-4 homozygous mice. In hCTLA-4 mice, treatment with αhCTLA-4 (ipilimumab) injection can inhibit tumor growth and prolong the life of mice.